Funding to successfully finalise EDCTP2-funded clinical trials that were negatively impacted by the COVID-19 pandemic
This program provides crucial funding to ensure the successful finalization of clinical trials initiated under the EDCTP2 program that faced disruptions due to the COVID-19 pandemic. Its main objective is to enable the conclusion of these vital medical technology trials, ensuring their results can inform healthcare professionals and strengthen public health systems, particularly in sub-Saharan Africa. The initiative emphasizes global health impact, aiming to deliver immediate public health relevance.
Who is Funded
This section outlines the eligibility criteria for applicants, the geographical scope of the program, and its overarching objectives. It details who can apply, where projects should be implemented, and the strategic goals this funding aims to achieve. The program specifically targets clinical trials focused on public health challenges in sub-Saharan Africa.
What is Funded
This section details the types of projects, thematic areas, and activities supported by the program, specifically focusing on clinical trials in various public health domains. It also outlines the developmental stages of projects eligible for this targeted funding.
Type and Scope of Funding
This section outlines the financial nature of the support provided by the program, including the type of financial instrument, the minimum and maximum funding amounts available per project, and expected grant numbers.
Conditions and Requirements
This section details the essential rules, regulations, and specific conditions that applicants and beneficiaries must adhere to throughout the application process and project implementation, including consortium structure and exploitation obligations.
Application Procedure
This section outlines the process for submitting applications, including the required forms and the criteria by which proposals are evaluated and selected.
Legal Basis
This section identifies the foundational legal and official documents that govern the funding program, including the primary regulation establishing it and other key policies influencing its operation.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
2,500,000 €
Allocated Budget:
14,000,000 €
Open Until:
31.12.2027
Award Channel:
Framework Programme Call
Region:
European Union Member States and their Overseas Countries and Territories, countries associated with Horizon Europe (Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine), and low- and middle-income countries which are constituent states of the EDCTP Association (Burkina Faso, Cameroon, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda, Zambia, Zimbabwe). Entities from Russia, Belarus, or non-government-controlled territories of Ukraine are excluded.
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development
Beneficiaries:
Global Health, Infectious Diseases, Public Health, Clinical Research, Clinical Trials, Health Systems
Application Type:
Consortium Required
Funding Stages:
Experimental Development, Market Introduction, Commercialization, Implementation
Funding Provider
Program Level:
European Union
Funding Body:
European Commission, Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU)
Managed By:
Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU)
Website: